This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
162
Darifenacin tablets 15 mg once daily
Tolterodine extended release (ER) 4 mg once daily
Placebo tablet once daily
Investigative Site
Scottsdale, Arizona, United States
Investigative Site
Tempe, Arizona, United States
Investigative Site
San Diego, California, United States
Mean heart rate per 24 hours following exposure to darifenacin 15 mg o.d. and tolterodine ER 4 mg o.d., at baseline and Day 7
Effects of darifenacin and tolterodine compared to placebo on mean heart rate per 24 hours, at baseline and Day 7
Effects of darifenacin, tolterodine and placebo on other cardiovascular parameters at baseline and Day 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Investigative Site
Jacksonville, Florida, United States
Investigative Site
Jupiter, Florida, United States
Investigative Site
Overland Park, Kansas, United States
Investigative Site
Madisonville, Kentucky, United States
Investigative Site
Wellesley Hills, Massachusetts, United States
Investigative Site
Hackensack, New Jersey, United States
Investigative Site
Buffalo, New York, United States
...and 2 more locations